VERAXA Biotech AG (NASDAQ: VRXA) has taken a significant step forward in the clinical development of its lead BiTAC-TCE cancer therapy, following receipt of favorable Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI). This regulatory guidance provides clarity on the program's biological rationale, pharmacokinetics, and planned non-clinical safety studies, thereby reducing development uncertainty and clarifying the path toward the clinic. The company views this early regulatory validation as a crucial milestone in advancing its next-generation cancer therapy.
The PEI's feedback is particularly valuable as it addresses key aspects of the BiTAC-TCE program, which is designed to selectively target cancer cells carrying two biomarkers while sparing cells with only one. This dual-targeting approach has the potential to improve the therapeutic window of conventional T-cell engagers, potentially leading to better efficacy and fewer side effects. The company previously presented encouraging preclinical results at the 2026 AACR Annual Meeting, which highlighted the selective targeting capabilities of its lead candidate.
With this regulatory guidance in hand, VERAXA is now focused on completing non-clinical studies, advancing manufacturing processes, and preparing for future regulatory submissions. The company's commitment to rigorous quality-by-design principles is evident in its approach to development. "The PEI's advice is a strong endorsement of our development strategy," said a company spokesperson. "It provides us with a clear roadmap for advancing our BiTAC-TCE therapy toward clinical trials, and we are excited about the potential to bring this innovative treatment to patients in need."
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T-cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. VERAXA's pipeline is rapidly advancing, with a focus on addressing unmet medical needs in oncology.
The broader oncology pipeline at VERAXA includes a range of engineered antibody therapies designed to harness the power of the immune system to fight cancer. The company's proprietary BiTAC formats are at the forefront of this effort, and the recent regulatory guidance is a testament to the potential of these therapies. As VERAXA moves forward, it remains dedicated to advancing its pipeline into clinical development and beyond, with the ultimate goal of improving outcomes for cancer patients.
Investors and stakeholders can find the latest news and updates about VERAXA Biotech in the company's newsroom at https://ibn.fm/VRXA. For more information about the company and its pipeline, visit www.VERAXA.com.
